Premium
Hospitalization for serious blood and skin disorders followinguse of co‐trimoxazole
Author(s) -
Myers Marian Wald,
Jick Hershel
Publication year - 1997
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1046/j.1365-2125.1997.00584.x
Subject(s) - medicine , intensive care medicine , emergency medicine
Aims The objective of this study was to quantify the risk of serious blood and skin disorders associated with co‐trimoxazole. Methods We conducted a population‐based cohort study of serious blood and skin disorders requiring hospitalization among otherwise healthy users of co‐trimoxazole at Group Health Cooperative and Puget Sound (GHC). Results During the years 1987 to 1993 we found six cases of co‐trimoxazole‐associated blood disorders and three cases of co‐trimoxazole‐associated skin disorders yielding risks of 5.6/100 000 (95% CI 2.6–12.2) and 2.8/100 000 (95% CI 0.9–8.2) respectively. In all cases found there was prompt recovery after discontinuation of co‐trimoxazole. We found no cases of toxic epidermal necrolysis. Conclusions We conclude that the risk of blood and skin disorders associated with the use of co‐trimoxazole leading to hospitalization is low.